United States

Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products.

We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.

With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), we believe there are multiple therapeutic areas where our PTR technology may be employed to develop additional product candidates, notably anxiety disorders.

Psychological Diseases

Cingulate Inc

Attention deficit hyperactivity disorder

Mental health

<p class="font_8">CTx-1301 (dexmethylphenidate)</p>

CTx-1301 

Small Molecule Pharmaceuticals

Ctx-1302

CTx-1302  

Anxiety Disorders

<p class="font_8">CTx-2103 is a novel, trimodal, extended-release tablet of buspirone that incorporates Cingulate’s proprietary PTR™ drug delivery platform. CTx-2103 is being studied for the treatment of anxiety and/or anxiety-related disorders. Buspirone, an azapirone derivative and a 5-HT1A partial agonist, was the first non-benzodiazepine anxiolytic introduced for the treatment of generalized anxiety disorder. Buspirone may exhibit a decreased side-effect profile compared to other anxiolytic treatments. Unlike benzodiazepines and barbiturates, there is no associated risk of physical dependence or withdrawal with buspirone use due to the lack of effects on gamma-aminobutyric acid receptors.</p>

Cingulate Inc

Company Details